Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of plozasiran in adults with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) Congress 2026.</li><li>Both studies met their primary endpoint with median triglyceride reductions from baseline of 79% and 81%, respectively.</li><li>In addition, more than 90% of treated patients achieved triglyceride levels <500 mg/dL, which is below the threshold for sHTG.</li></ul>

On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of plozasiran in adults with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) Congress 2026.Both studies met their primary endpoint with median triglyceride reductions from baseline of 79% and 81%, respectively.In addition, more than 90% of treated patients achieved triglyceride levels 

ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul>
<li>Arrowhead Pharmaceuticals reported its fiscal third quarter results for 2026, highlighting significant developments primarily centered on plozasiran and its expansion potential.</li>
<li>The company announced positive top-line Phase III data from the SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia (sHTG), with both studies meeting primary and all prespecified secondary endpoints.</li>
<li>Median triglyceride reductions were 79% and 81%, respectively, demonstrating deep and durable effects.</li>
</ul>


Arrowhead Pharmaceuticals reported its fiscal third quarter results for 2026, highlighting significant developments primarily centered on plozasiran and its expansion potential.
The company announced positive top-line Phase III data from the SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia (sHTG), with both studies meeting primary and all prespecified secondary endpoints.
Median triglyceride reductions were 79% and 81%, respectively, demonstrating deep and durable effects.


Arrowhead Pharmaceuticals & Madrigal — Strategic Partnerships Broaden The RNAi Growth Engine!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Arrowhead is a leader in RNA interference (RNAi) therapeutics, leveraging its proprietary TRiM™ platform to develop a deep pipeline of gene-silencing drugs for intractable diseases.</li>
  <li>The company's lead wholly-owned candidate, plozasiran, has demonstrated highly positive Phase 3 data in severe hypertriglyceridemia (sHTG), with a supplemental New Drug Application (sNDA) planned for submission by the end of 2026.</li>
  <li>Valuation is primarily driven by the clinical and commercial success of its pipeline, making it subject to high uncertainty related to trial outcomes, regulatory approvals, and competition from established players in the RNAi space.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Arrowhead is a leader in RNA interference (RNAi) therapeutics, leveraging its proprietary TRiM™ platform to develop a deep pipeline of gene-silencing drugs for intractable diseases.
  The company's lead wholly-owned candidate, plozasiran, has demonstrated highly positive Phase 3 data in severe hypertriglyceridemia (sHTG), with a supplemental New Drug Application (sNDA) planned for submission by the end of 2026.
  Valuation is primarily driven by the clinical and commercial success of its pipeline, making it subject to high uncertainty related to trial outcomes, regulatory approvals, and competition from established players in the RNAi space.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Arrowhead Pharmaceuticals  (ARWR US) - Aug 2026

<ul><li>On August 4, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2026 that ended June 30, 2026.</li><li>The company recently announced positive results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG), which included a statistically significant reduction in acute pancreatitis (AP) events versus placebo.</li><li>The company will be presenting detailed trial results at the European Society of Cardiology (ESC) Congress on August 30, 2026 and a conference call and webcast is scheduled for August 31, 2026 to discuss the results.</li></ul>

On August 4, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2026 that ended June 30, 2026.The company recently announced positive results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG), which included a statistically significant reduction in acute pancreatitis (AP) events versus placebo.The company will be presenting detailed trial results at the European Society of Cardiology (ESC) Congress on August 30, 2026 and a conference call and webcast is scheduled for August 31, 2026 to discuss the results.

ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG

<ul><li>On July 22, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced positive results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG).</li><li>The results shared by the company included a 79% and 81% median triglyceride reduction from baseline in SHASTA-3 and SHASTA-4, respectively.</li><li>In addition, Arrowhead reported a statistically significant reduction in acute pancreatitis (AP) events versus placebo, including a 100% event reduction in high-risk patients (TG > 880 mg/dL and a history of AP).</li></ul>

On July 22, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced positive results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG).The results shared by the company included a 79% and 81% median triglyceride reduction from baseline in SHASTA-3 and SHASTA-4, respectively.In addition, Arrowhead reported a statistically significant reduction in acute pancreatitis (AP) events versus placebo, including a 100% event reduction in high-risk patients (TG > 880 mg/dL and a history of AP).

ARWR: SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients

United States

Arrowhead Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicines that treat intractable diseases by silencing the genes. Arrowhead Pharmaceuticals offers its services in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arrowhead Pharmaceuticals (ARWR US)

ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026

On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of...

Zacks Small Cap Research

Arrowhead Pharmaceuticals & Madrigal — Strategic Partnerships Broaden The RNAi Growth Engine!

Arrowhead Pharmaceuticals reported its fiscal third quarter results for 2026, highlighting significant developments primarily centered on...

Baptista Research

Primer: Arrowhead Pharmaceuticals (ARWR US) - Aug 2026

Arrowhead is a leader in RNA interference (RNAi) therapeutics, leveraging its proprietary TRiM™ platform to develop a deep pipeline of...

αSK Primers

ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG

On August 4, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2026 that ended June...

Zacks Small Cap Research

ARWR: SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients

On July 22, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced positive results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)